These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 35015123

  • 1. The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants.
    Méaux MN, Sellier-Leclerc AL, Acquaviva-Bourdain C, Harambat J, Allard L, Bacchetta J.
    Pediatr Nephrol; 2022 Apr; 37(4):907-911. PubMed ID: 35015123
    [Abstract] [Full Text] [Related]

  • 2. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
    Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D.
    Am J Kidney Dis; 2023 Feb; 81(2):145-155.e1. PubMed ID: 35843439
    [Abstract] [Full Text] [Related]

  • 3. Nephrocalcinosis can disappear in infants receiving early lumasiran therapy.
    Kayal D, Sellier-Leclerc AL, Acquaviva-Bourdain C, de Mul A, Cabet S, Bacchetta J.
    Pediatr Nephrol; 2024 Jul; 39(7):2079-2082. PubMed ID: 38261066
    [Abstract] [Full Text] [Related]

  • 4. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
    Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC, ILLUMINATE-A Collaborators.
    N Engl J Med; 2021 Apr 01; 384(13):1216-1226. PubMed ID: 33789010
    [Abstract] [Full Text] [Related]

  • 5. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
    Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P, study collaborators.
    Clin J Am Soc Nephrol; 2021 Jul 01; 16(7):1025-1036. PubMed ID: 33985991
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial.
    Frishberg Y, Hayes W, Shasha-Lavsky H, Sas DJ, Michael M, Sellier-Leclerc AL, Hogan J, Willey R, Gansner JM, Magen D.
    Front Pediatr; 2024 Jul 01; 12():1392644. PubMed ID: 39355649
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.
    Hayes W, Sas DJ, Magen D, Shasha-Lavsky H, Michael M, Sellier-Leclerc AL, Hogan J, Ngo T, Sweetser MT, Gansner JM, McGregor TL, Frishberg Y.
    Pediatr Nephrol; 2023 Apr 01; 38(4):1075-1086. PubMed ID: 35913563
    [Abstract] [Full Text] [Related]

  • 8. Lumasiran: A Review in Primary Hyperoxaluria Type 1.
    Kang C.
    Drugs; 2024 Feb 01; 84(2):219-226. PubMed ID: 38252335
    [Abstract] [Full Text] [Related]

  • 9. Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1.
    Hulton SA, Groothoff JW, Frishberg Y, Koren MJ, Overcash JS, Sellier-Leclerc AL, Shasha-Lavsky H, Saland JM, Hayes W, Magen D, Moochhala SH, Coenen M, Simkova E, Garrelfs SF, Sas DJ, Meliambro KA, Ngo T, Sweetser MT, Habtemariam BA, Gansner JM, McGregor TL, Lieske JC.
    Kidney Int Rep; 2022 Mar 01; 7(3):494-506. PubMed ID: 35257062
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Bilateral nephrocalcinosis: primary hyperoxaluria involved].
    Deprez T, Sempels M.
    Rev Med Liege; 2022 Jul 01; 77(7-8):416-420. PubMed ID: 35924494
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lumasiran for primary hyperoxaluria type 1: What we have learned?
    Gang X, Liu F, Mao J.
    Front Pediatr; 2022 Jul 01; 10():1052625. PubMed ID: 36704142
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Infantile Primary Hyperoxaluria Type 1 Treated With Lumasiran in Twin Males.
    Aldabek K, Grossman OK, Al-Omar O, Fox JA, Moritz ML.
    Cureus; 2022 Jan 01; 14(1):e21673. PubMed ID: 35237473
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Case Report: effect of lumasiran treatment in a late preterm baby with antenatal diagnosis of primary hyperoxaluria type 1.
    Taroni F, Berrettini A, Gnech M, Rella F, Manzoni GA, Montini G.
    Front Pediatr; 2023 Jan 01; 11():1338909. PubMed ID: 38293660
    [Abstract] [Full Text] [Related]

  • 19. Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1.
    Martin-Higueras C, Borghese L, Torres A, Fraga-Bilbao F, Santana-Estupiñán R, Stefanidis CJ, Tory K, Walli A, Gondra L, Kempf C, Gessner M, Habbig S, Eifler L, Schmitt CP, Rüdel B, Bartram MP, Beck BB, Hoppe B.
    Kidney Int Rep; 2024 Jan 01; 9(1):114-133. PubMed ID: 38312792
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.